Peak poised to enter market with $21m series C:
This article was originally published in Clinica
Peak Surgical, a Palo Alto, California-based developer of tissue dissection systems, has raised $21m in a series C financing led by new investor Signet Healthcare Partner. The proceeds will enable Peak to commence commercialisation of its flagship product, the Peak surgery system, which incorporates the firm's pulsed plasma technology. The company is awaiting 510(k) clearance from the US FDA for the product and has begun setting up a nationwide sales team, as well as manufacturing for the Peak PlasmaBlade, an integral part of the surgery system.
You may also be interested in...
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called front rooms, where US FDA investigators do the majority of their work during facility inspections. See what he said here.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, the Chinese government maintains that the situation is “preventable and controllable.”